Biocryst Pharmaceuticals Stock Operating Margin
BCRX Stock | USD 5.15 0.14 2.79% |
BioCryst Pharmaceuticals fundamentals help investors to digest information that contributes to BioCryst Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of BioCryst Stock. The fundamental analysis module provides a way to measure BioCryst Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to BioCryst Pharmaceuticals stock.
BioCryst | Operating Margin |
BioCryst Operating Margin Analysis
BioCryst Pharmaceuticals' Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.
More About Operating Margin | All Equity Analysis
2021 | 2022 | 2023 | 2024 (projected) | Short and Long Term Debt Total | 593.2M | 741.5M | 848.7M | 891.1M | Total Assets | 588.2M | 550M | 517.0M | 542.8M |
Operating Margin | = | Operating IncomeRevenue | X | 100 |
Current BioCryst Pharmaceuticals Operating Margin | (0.40) % |
Most of BioCryst Pharmaceuticals' fundamental indicators, such as Operating Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, BioCryst Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
BioCryst Operating Margin Driver Correlations
Understanding the fundamental principles of building solid financial models for BioCryst Pharmaceuticals is extremely important. It helps to project a fair market value of BioCryst Stock properly, considering its historical fundamentals such as Operating Margin. Since BioCryst Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of BioCryst Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of BioCryst Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.
Competition |
BioCryst Pretax Profit Margin
Pretax Profit Margin |
|
Based on the recorded statements, BioCryst Pharmaceuticals has an Operating Margin of -0.4041%. This is 98.85% lower than that of the Biotechnology sector and 99.64% lower than that of the Health Care industry. The operating margin for all United States stocks is 92.67% lower than that of the firm.
BioCryst Operating Margin Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses BioCryst Pharmaceuticals' direct or indirect competition against its Operating Margin to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of BioCryst Pharmaceuticals could also be used in its relative valuation, which is a method of valuing BioCryst Pharmaceuticals by comparing valuation metrics of similar companies.BioCryst Pharmaceuticals is currently under evaluation in operating margin category among related companies.
BioCryst Fundamentals
Return On Equity | -19.25 | ||||
Return On Asset | -0.12 | ||||
Profit Margin | (0.68) % | ||||
Operating Margin | (0.40) % | ||||
Current Valuation | 1.47 B | ||||
Shares Outstanding | 206.15 M | ||||
Shares Owned By Insiders | 1.22 % | ||||
Shares Owned By Institutions | 88.05 % | ||||
Number Of Shares Shorted | 30.55 M | ||||
Price To Earning | (7.11) X | ||||
Price To Book | 56.59 X | ||||
Price To Sales | 3.20 X | ||||
Revenue | 331.41 M | ||||
Gross Profit | 10.94 M | ||||
EBITDA | (102.05 M) | ||||
Net Income | (226.54 M) | ||||
Cash And Equivalents | 417.48 M | ||||
Cash Per Share | 2.24 X | ||||
Total Debt | 848.71 M | ||||
Debt To Equity | 2.40 % | ||||
Current Ratio | 5.19 X | ||||
Book Value Per Share | (2.21) X | ||||
Cash Flow From Operations | (95.14 M) | ||||
Short Ratio | 9.88 X | ||||
Earnings Per Share | (1.18) X | ||||
Price To Earnings To Growth | (0.28) X | ||||
Target Price | 13.82 | ||||
Number Of Employees | 536 | ||||
Beta | 1.92 | ||||
Market Capitalization | 1.06 B | ||||
Total Asset | 516.96 M | ||||
Retained Earnings | (1.68 B) | ||||
Working Capital | 345.98 M | ||||
Current Asset | 65.99 M | ||||
Current Liabilities | 64.45 M | ||||
Z Score | -3.01 | ||||
Net Asset | 516.96 M |
About BioCryst Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze BioCryst Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of BioCryst Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of BioCryst Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina. Biocryst Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 358 people.
Pair Trading with BioCryst Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if BioCryst Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in BioCryst Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving together with BioCryst Stock
0.61 | MBRX | Moleculin Biotech Upward Rally | PairCorr |
0.77 | MCRB | Seres Therapeutics Financial Report 14th of May 2024 | PairCorr |
Moving against BioCryst Stock
0.66 | DNTH | Dianthus Therapeutics Symbol Change | PairCorr |
0.56 | MGNX | MacroGenics Financial Report 14th of May 2024 | PairCorr |
0.53 | MDWD | Mediwound Financial Report 4th of June 2024 | PairCorr |
0.44 | EQ | Equillium Financial Report 9th of May 2024 | PairCorr |
0.43 | MRK | Merck Company Fiscal Quarter End 31st of March 2024 | PairCorr |
The ability to find closely correlated positions to BioCryst Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace BioCryst Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back BioCryst Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling BioCryst Pharmaceuticals to buy it.
The correlation of BioCryst Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as BioCryst Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if BioCryst Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for BioCryst Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out BioCryst Pharmaceuticals Piotroski F Score and BioCryst Pharmaceuticals Altman Z Score analysis. For more information on how to buy BioCryst Stock please use our How to Invest in BioCryst Pharmaceuticals guide.You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.
Complementary Tools for BioCryst Stock analysis
When running BioCryst Pharmaceuticals' price analysis, check to measure BioCryst Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioCryst Pharmaceuticals is operating at the current time. Most of BioCryst Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of BioCryst Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioCryst Pharmaceuticals' price. Additionally, you may evaluate how the addition of BioCryst Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
Content Syndication Quickly integrate customizable finance content to your own investment portal | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
Insider Screener Find insiders across different sectors to evaluate their impact on performance |
Is BioCryst Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BioCryst Pharmaceuticals. If investors know BioCryst will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BioCryst Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.18) | Revenue Per Share 1.724 | Quarterly Revenue Growth 0.174 | Return On Assets (0.12) | Return On Equity (19.25) |
The market value of BioCryst Pharmaceuticals is measured differently than its book value, which is the value of BioCryst that is recorded on the company's balance sheet. Investors also form their own opinion of BioCryst Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is BioCryst Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BioCryst Pharmaceuticals' market value can be influenced by many factors that don't directly affect BioCryst Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between BioCryst Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if BioCryst Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BioCryst Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.